title: [Choroidal thickness after half-dose verteporfin photodynamic therapy in chronic central serous chorioretinopathy].
abstract: OBJECTIVE
  To observe the choroidal thickness in eyes with chronic central serous chorioretinopathy(CSC) after half-dose photodynamic therapy(PDT).
  
  
  METHODS
  Case series study. Consecutive 30 patients (35 eyes) with chronic CSC admitted from October 2010 to October 2011 in Zhongshan Ophthalmic Center were recruited in this study. Optical coherence tomography(OCT),fundus fluorescein angiography, indocyanine green angiography (ICGA) were performed in each patient to confirm the diagnosis. ICGA-guided PDT was performed in each patient. Choroidal thickness at subfoveal and 1500 µm superior, inferior, nasal and temporal to the fovea were measured before PDT, 1, 3 and 6 months after PDT using enhanced depth imaging OCT. Data were analyzed with one-way repeated measures ANOVA and LSD-t test when pairwise comparison was needed.
  
  
  RESULTS
  Thirty patients, aged from 33 to 66 years old, including 26 males and 4 females (gender ratio 6.5: 1) were recruited. Subfoveal choroidal thickness (SFCT) in chronic CSC eyes was (435.54 ± 102.91) µm at baseline,which decreased significantly to (373.63 ± 106.01) µm, (360.69 ± 111.06) µm and (369.00 ± 108.12) µm at 1 month, 3 months and 6 months after PDT respectively (F = 108.34, P < 0.01). At 6 months after PDT, SFCT was slightly thicker than that at the 3(rd) month,but no statistical significance was noted (LSD-t test: P > 0.05). The changing trends of choroidal thickness at the other 4 measuring points were similar to that of the SFCT.
  
  
  CONCLUSIONS
  Choroidal thickness is reduced within 6 months post PDT in chronic CSC eyes.
authors.affiliation: State Key Laboratory of Ophthalmology,Sun Yat-Sen University, Zhongshan Ophthalmic Center,Guangzhou 510060,China.
authors.forename: Jing
authors.initials: J
authors.lastname: Zeng
authors.forename: Yuan-yuan
authors.initials: YY
authors.lastname: Yan
authors.forename: Xiao-yan
authors.initials: XY
authors.lastname: Ding
authors.forename: Ran
authors.initials: R
authors.lastname: Liu
authors.forename: Jia-qing
authors.initials: JQ
authors.lastname: Li
mesh_terms: D000328:Adult; D000368:Aged; D056833:Central Serous Chorioretinopathy / Q000188:drug therapy* / Q000473:pathology; D002829:Choroid / Q000473:pathology; D002908:Chronic Disease; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy / Q000379:methods; D017319:Photosensitizing Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D011166:Porphyrins / Q000008:administration & dosage* / Q000627:therapeutic use; D041623:Tomography, Optical Coherence; D000077362:Verteporfin
chemical_list: D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin